Cost analysis with censored data.
暂无分享,去创建一个
[1] B. O'brien. Outcomes Assessment in Cancer: Cost-effectiveness analysis in cancer: toward an iterative framework for integration of evidence from trials and models , 2004 .
[2] E. Feuer,et al. Estimating medical costs from incomplete follow-up data. , 1997, Biometrics.
[3] Thomas A. Louis,et al. Nonparametric estimation of the joint distribution of survival time and mark variables , 1998 .
[4] D. Horvitz,et al. A Generalization of Sampling Without Replacement from a Finite Universe , 1952 .
[5] J. Robins,et al. Recovery of Information and Adjustment for Dependent Censoring Using Surrogate Markers , 1992 .
[6] Laurence L. George,et al. The Statistical Analysis of Failure Time Data , 2003, Technometrics.
[7] Anastasios A. Tsiatis,et al. Estimating medical costs with censored data , 2000 .
[8] Nicholas P. Jewell,et al. AIDS epidemiology : methodological issues , 1993 .
[9] H Zhao,et al. On Estimating Medical Cost and Incremental Cost‐Effectiveness Ratios with Censored Data , 2001, Biometrics.
[10] Anastasios A Tsiatis,et al. Median Regression with Censored Cost Data , 2002, Biometrics.
[11] D. Lin,et al. Regression analysis of incomplete medical cost data , 2003, Statistics in medicine.
[12] Robert L. Strawderman,et al. Estimating the Mean of an Increasing Stochastic Process at a Censored Stopping Time , 2000 .
[13] J. Crowley,et al. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. , 2002, Journal of the National Cancer Institute.
[14] P Fenn,et al. The Analysis of Censored Treatment Cost Data in Economic Evaluation , 1995, Medical care.
[15] H. Bang. Medical cost analysis: application to colorectal cancer data from the SEER Medicare database. , 2005, Contemporary clinical trials.
[16] J. Robins,et al. Estimation of Regression Coefficients When Some Regressors are not Always Observed , 1994 .
[17] B. Efron. The two sample problem with censored data , 1967 .
[18] Hongwei Zhao,et al. On the equivalence of some medical cost estimators with censored data. , 2007, Statistics in medicine.
[19] TESTS FOR LIFETIME UTILITY OR COST VIA CALIBRATING SURVIVAL TIME , 2002 .
[20] J Lipscomb,et al. The burden of illness of cancer: economic cost and quality of life. , 2001, Annual review of public health.
[21] J. Crowley,et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] D. Lin,et al. Linear regression analysis of censored medical costs. , 2000, Biostatistics.
[23] Yijian Huang,et al. Calibration Regression of Censored Lifetime Medical Cost , 2002 .